Key result
Athlete-optimized cut-offs identify dyslipidemia in ~36% of Olympic athletes, though high risk remains rare.
Why the study?
Data on cardiovascular risk profiles and dyslipidemia in large cohorts of competitive athletes are scarce, and specific risk assessment tools for athletes are lacking.
Observational (n=957)
No
Standard tools may misclassify athletes; leaves open whether novel scores improve risk stratification in elite sports.
The treatment of lipid disorders in athletes presents several unique issues. The effects of exercise on lipid subfractions are explained and the evidence supporting the treatment of dyslipidemia is reviewed. Screening for dyslipidemia with a discussion of novel risk factor assessment is examined. The National Cholesterol Education Program Adult Treatment Panel III treatment guidelines are presented as a template for the management of dyslipidemia in athletes. Special cautions in the use of statins in athletes, as well as complementary and alternative medical treatments are discussed. Treatment regimens must be tailored to both the risk status and sport of each individual athlete.
No takes yet. Share an insight, caveat, or question.
Reamy et al. (2004) conducted an observational in Dyslipidemia (n=957). Elite athletic training was evaluated on Prevalence of dyslipidemia (defined as LDL ≥ 115 mg/dL or LDL/HDL ratio ≥ 1.90). Among 957 elite Olympic athletes, 35.8% met criteria for dyslipidemia using athlete-optimized cut-offs, though only 1.2% were classified as high cardiovascular risk by a novel lipid athlete score.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: